Clinical Trial Finder

Inclusion Criteria:

• - Age ≥18 years of age at the time consent is signed.

• - Has adequate end organ function per laboratory testing.

• - Pregnancy prevention requirements.

• - Has measurable disease per RECIST 1.1 as assessed by the local site Investigator/radiology.

• - Has a performance status of 0 or 1 on Eastern Cooperative Oncology Group scale.

• - Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts.

Exclusion Criteria:

• - Has a diagnosis of immunodeficiency.

• - Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.

• - Has known active CNS metastases and/or carcinomatous meningitis.

• - Has an active autoimmune disease that has required systemic treatment in the past 2 years.

• - Has an active infection requiring systemic therapy.

• - Inability to comply with study and follow-up procedures.

• - Has had a severe hypersensitivity reaction (Grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients.

• - Has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.

• - Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.

• - Receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.

• - Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.

- Is expected to require any other form of antineoplastic therapy while on study

Arms

Experimental: etakafusp alfa (AB248) Monotherapy Dose-Escalation

etakafusp alfa (AB248) will be administered intravenously as a single agent

Experimental: etakafusp alfa (AB248) + pembrolizumab Combination Dose-Escalation

etakafusp alfa (AB248) and pembrolizumab will be administered intravenously

Experimental: etakafusp alfa (AB248) Monotherapy Indication Expansion

etakafusp alfa (AB248) will be administered intravenously as a single agent in disease specific cohorts

Experimental: etakafusp alfa (AB248) + pembrolizumab Combination Indication Expansion

etakafusp alfa (AB248) and pembrolizumab will be administered intravenously in disease specific cohorts

Interventions

Biological: - etakafusp alfa (AB248)

Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug

Biological: - pembrolizumab

Intravenous infusion of pembrolizumab